STAAR Surgical Company filings document the regulatory record for a NASDAQ-listed ophthalmic device company focused on phakic IOLs and the EVO family of Implantable Collamer® Lenses. Its reports and exhibits cover operating results, preliminary sales disclosures, shareholder letters, product and market commentary, and clinical or regulatory matters tied to lens-based vision correction.
Recent filings also address proxy and governance disclosure, shareholder voting matters, board and committee composition, director independence, executive appointments and separation arrangements, material agreements, capital-structure disclosure for common stock, and the termination of a previously disclosed merger agreement.
STAAR SURGICAL CO is the issuer named in BlackRock, Inc.'s Amendment No. 20 to Schedule 13G, which reports beneficial ownership of 4,611,827 common shares, or 9.2% of the class. BlackRock reports sole voting power over 4,534,467 shares and sole dispositive power over 4,611,827 shares, with zero shared voting or dispositive power. Various persons have the right to receive dividends or sale proceeds, but no one person's interest exceeds 5% of total outstanding common shares.
STAAR Surgical Company appointed David Bailey as Chief Commercial Officer effective September 8, 2026. The amended compensation disclosure corrects the allocation of equity awards to match his offer letter; the previously stated award dollar values were correct.
Bailey's annual base salary is CHF 462,825 (approximately $575,000), prorated in 2026 based on his Start Date, and his fiscal 2026 cash bonus target is 60% of base salary, also prorated. His initial equity grant, valued at $850,000 and to be granted on the Start Date, is split 50% restricted stock units (RSUs) and 50% stock options. The RSUs vest in thirds on the first, second and third grant anniversaries; the options vest over three years. His 2026 annual long-term incentive award is valued at $1,400,000, prorated based on his Start Date, and split evenly between options and RSUs.
STAAR Surgical Company (STAA) appointed former CEO David Bailey as Chief Commercial Officer, effective September 8, 2026. He joins the executive committee and reports to President and CEO Warren Foust. Bailey previously led STAAR as President and CEO from 2001 to 2008 and President of International Operations from 2008 to 2011.
Under his offer letter, Bailey receives a base salary of CHF 462,825 (approximately $575,000) per year, with a target 2026 cash bonus equal to 60% of base salary, both prorated from his start date. He will receive an initial RSU grant valued at $850,000, vesting in three equal annual installments, and a prorated 2026 long‑term incentive award valued at $1,400,000, split 50% stock options and 50% RSUs. The company highlights his earlier tenure, during which it reports raising more than $60 million, securing FDA approval of the ICL in 2005, and growing ICL revenues to about $32 million by 2011, and notes that more than 4 million ICLs have been sold in over 85 countries to date.
STAAR SURGICAL CO (STAA) reported multiple equity awards to President and CEO Warren Foust on August 14, 2026. He received 22,493 restricted stock units, each RSU convertible into one share of common stock, vesting over three years. He was granted stock options for 40,471 and 37,962 shares at an exercise price of $26.18 per share, plus performance stock options for 131,830 and 123,659 shares, also at $26.18, which vest based on both time and stock-price hurdles of $50.00, $75.00 and $100.00 per share. In addition, third tranches of performance stock units of 7,331 and 3,666 units vested, settling into common stock, with 3,730 and 1,865 shares, respectively, withheld to satisfy taxes.
STAAR Surgical Co (STAA) reported equity compensation and vesting events for its Chief Financial Officer & EVP, Deborah J. Andrews. On August 14, 2026, she received 4,975 Restricted Stock Units, plus a stock option for 8,952 shares at an exercise price of $26.18 per share expiring on August 13, 2036. She also received a performance stock option for 29,159 shares at $26.18 per share, vesting over a performance period with stock-price hurdles of $50.00, $75.00 and $100.00 per share and additional time-vesting conditions. Separately, the third tranche of 5,233 performance stock units under the 2025 PSU Program vested, converting into common shares, of which 2,662 shares were withheld to satisfy taxes.
STAAR SURGICAL CO (STAA) reported that Chief Development Officer Magda Michna settled and exercised performance-based equity awards on August 14, 2026. A third tranche of 5,499 performance stock units from her 2025 annual equity grant and 1,100 units from a promotion-related grant were settled into common stock, totaling 6,599 shares acquired. Of these, 2,797 shares were withheld to satisfy taxes and an additional 559 shares were delivered or withheld for payment of exercise price or tax liability. The company also corrected prior Form 4 filings to reflect lower historical beneficial ownership values.
STAAR Surgical Company received an updated ownership report from a group of investment entities associated with Eli Samaha. As of June 30, 2026, Madison Avenue International LP beneficially owned 4,175,748 shares of Common Stock. Through various control relationships, Madison Avenue Partners, LP, EMAI Management, LLC, Madison Avenue GP, LLC, Caraway Jackson Investments LLC, and Mr. Samaha may each be deemed beneficial owners of the same shares. Based on 49,788,495 shares of Common Stock outstanding as of May 8, 2026, this position represents approximately 8.4% of STAAR Surgical’s outstanding Common Stock.
STAAR Surgical Company reported a strong turnaround for the quarter ended July 3, 2026. Net sales reached $93.5 million, up 111.0% from $44.3 million a year earlier, driven mainly by China, where two distributors generated $52.3 million of sales and 56% of quarterly revenue. Gross margin was 74.5%, slightly above 74.0% last year, reflecting cost reductions, partly offset by tariffs and higher unit costs during the ramp-up of the new Swiss facility.
Operating income was $10.1 million versus a loss of $(29.9) million, and net income was $8.1 million or $0.16 per diluted share compared with a loss of $(16.8) million or $(0.34) per share. For the first six months, net sales were $187.1 million and net income $13.3 million, versus a $(71.0) million loss in 2025, as prior-year restructuring and impairment charges of $27.9 million did not recur at the same scale.
Cash and investments available for sale totaled $181.5 million at July 3, 2026, up from $163.9 million at April 3, 2026, while operating cash outflow for the first half narrowed to $2.0 million from $33.0 million. The company notes ongoing ERP implementation challenges and continuing tariff pressure until it can supply 100% of EVO and EVO+ ICL lenses for China from Switzerland.
STAAR Surgical Company reported a strong rebound for the second quarter ended July 3, 2026. Net sales were $93.5 million, up 111.0% year over year, with net sales excluding China of $41.2 million, up 6.0%. China contributed $52.3 million of sales, up over 100% year over year and 10% sequentially, and APAC sales overall rose 189% year over year. The Americas grew 12%, while EMEA declined 1%, though EMEA excluding the Middle East grew 12%.
Gross margin improved to 74.5% from 74.0%. The company swung to net income of $8.1 million, or $0.16 per diluted share, from a net loss of $(16.8) million, or $(0.34) per share, a year earlier. Adjusted EBITDA was $20.0 million, or $0.39 per diluted share, versus an Adjusted EBITDA loss of $(14.8) million a year ago. Operating income was $10.1 million, compared with an operating loss of $(30.0) million.
Cash, cash equivalents, and investments available for sale totaled $181.5 million at July 3, 2026, up from $163.9 million at the end of the first quarter of 2026, and the company reported no outstanding debt. Management highlighted strong EVO ICL adoption in China and Japan, double-digit growth in the Americas and EMEA ex-Middle East, and ongoing ERP and AI-related investments aimed at improving operating leverage.
STAAR Surgical Company appointed Warren Foust as President and Chief Executive Officer and a new member of the Board, effective August 4, 2026, after he had served as Interim Co‑CEO, President and COO. Deborah Andrews ends her Interim Co‑CEO role, continues as Chief Financial Officer, and is promoted to Executive Vice President.
Under an offer letter, Foust receives a base salary of $730,000, a 2026 cash bonus targeted at 70% of salary from the start of fiscal 2026 through January 31 and 100% thereafter, and equity grants of 22,493 RSUs, 40,471 time‑vesting options and 131,830 performance‑vesting options tied to $50, $75 and $100 share‑price hurdles, plus additional 2027 RSUs and options pulled forward. He also enters amended severance and change‑in‑control agreements providing 18 months of base pay and benefits, and in a change in control also earned and target bonus amounts, upon a qualifying termination. Andrews receives time‑ and performance‑based options for 8,952 and 29,159 shares and 4,975 RSUs aligned with her new EVP role under the omnibus equity plan.